Cyano Or Isocyano Bonded Directly To Carbon Patents (Class 514/519)
  • Patent number: 7863327
    Abstract: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: January 4, 2011
    Assignee: Trustees of Dartmouth College
    Inventors: Gordon W. Gribble, Tadashi Honda, Michael B. Sporn, Nanjoo Suh
  • Publication number: 20100298374
    Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.
    Type: Application
    Filed: May 14, 2010
    Publication date: November 25, 2010
    Applicant: CELLCEUTIX CORPORATION
    Inventor: Krishna MENON
  • Publication number: 20100272639
    Abstract: Polysaccharide nanoparticles that are particularly useful in for example drug and agent delivery, tissue-specific targeting, for medical imaging and diagnosis, as well as modifiers of physico-chemical properties. The nanoparticles can be highly-branched glucose homopolymers and can be characterized by a uniform spherical shape. They are monodisperse, hydrophilic and produce low solution viscosities. The nanoparticles are non-toxic, biocompatible and biodegradable. Also, the process of isolation of said polysaccharide nanoparticles from various organisms including, but not limited to, microorganisms such as bacteria and yeasts. Also provided are methods for chemical conjugation of the polysaccharide nanoparticles with various agents. Also provided are examples of use of the polysaccharide nanoparticles and their derivatives as drug delivery systems and fluorescent di-agnostics.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 28, 2010
    Inventor: John Robert Dutcher
  • Publication number: 20100215777
    Abstract: Compounds of formula (I) wherein the symbols have the meaning given in the specification, as well as processes for preparing the compounds (I), pesticidal compositions and synergistic mixtures comprising compounds (I), methods for the control of insects, acarids or nematodes by contacting the pests or their food supply, habitat or breeding grounds with a pesticidally effective amount of compounds formula (I), and a method for treating, controlling, preventing or protecting animals against infestation or infection by parasites which comprises orally, topically or parenterally administering or applying to the animals a parasiticidally effective amount of compounds of formula (I).
    Type: Application
    Filed: June 22, 2007
    Publication date: August 26, 2010
    Applicant: BASF SE
    Inventors: Matthias Pohlman, Michael Hofmann, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Hassan Oloumi-Sadeghi, Takeo Hokama, Christopher Palmer
  • Publication number: 20100215574
    Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 26, 2010
    Inventor: FELIX KRATZ
  • Publication number: 20100190750
    Abstract: The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
    Type: Application
    Filed: April 1, 2010
    Publication date: July 29, 2010
    Applicant: ARENA PHARMACEUTICALS, INC.
    Inventors: Zhi-Liang Chu, James N. Leonard, Juerg Lehmann, Robert M. Jones
  • Patent number: 7678830
    Abstract: Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: March 16, 2010
    Assignee: Trustees of Dartmouth College
    Inventors: Tadashi Honda, Frank G. Favaloro, Gordon W. Gribble, Michael B. Sporn, Nanjoo Suh
  • Patent number: 7655696
    Abstract: The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: February 2, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
  • Publication number: 20090239930
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: March 17, 2009
    Publication date: September 24, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Mark HOLOBOSKI, Robert M. BURK, Mari POSNER
  • Patent number: 7531573
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: May 12, 2009
    Assignee: Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellot, Jr., Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Patent number: 7488754
    Abstract: The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EGF receptor kinase inhibitor.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: February 10, 2009
    Assignee: Wyeth
    Inventors: Philip Frost, Jeremy I. Levin
  • Patent number: 7368123
    Abstract: According to the present invention, there is provided a pesticidal resin composition that contains (A) at least one resin selected from polyamide resins and polyacetal resins, (B) at least one compound selected from sulfone amide derivatives, sulfonic acid ester derivatives, phosphoric acid ester derivatives, phosphazene derivatives, carboxylic acid amide derivatives, carboxylic acid ester derivatives, and (C) a chemical agent having a pesticidal property. With the pesticidal resin composition containing the above ingredients, it is possible to obtain a pesticidal product that has such a strength, heat resistance and chemical resistance as to render the product usable as a structural member, as well as being capable of exhibiting the pesticidal activity for a prolonged period of time.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: May 6, 2008
    Assignees: Otsuka Kagaku Kabushiki Kaisha, NIX, Inc.
    Inventors: Akira Tabuchi, Kiyozumi Tani, Akiyoshi Inubushi, Atushi Kamada, Masaharu Kamei, Osamu Igarashi
  • Publication number: 20080090780
    Abstract: A storage stable, efficacious pesticide formulation is provided that is dilutable by the user and contains azadirachtin (AZA) and a pyrethrin or pyrethroid (PYR), and optionally an aprotic solvent and non-ionic, substantially water-free emulsifier. A sufficient amount of the PYR is provided to complex with the AZA A on opposite sides of the molecular structure thereof, thereby preventing rearrangement of the AZA A molecule in the presence of moisture that would result in hydrolysis and decomposition of AZA A. The AZA-PYR combination is sufficiently chemically stable such that less than 10% of the AZA A is decomposed when the formulation is subjected to an accelerated aging test for 30 days at 40° C. in a sealed container. The molar ratio of PYR to AZA A is preferably within the range of 0.5/1-10.5/1, more preferably within the range of 1.5/1-7/1, and most preferably with the range of 3/1-6/1.
    Type: Application
    Filed: October 13, 2006
    Publication date: April 17, 2008
    Applicant: PBI/GORDON CORPORATION
    Inventors: Dale R. Sanson, James A. Armbruster
  • Patent number: 7288568
    Abstract: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: October 30, 2007
    Assignee: Trustees of Dartmouth College
    Inventors: Gordon W. Gribble, Tadashi Honda, Michael B. Sporn, Nanjoo Suh
  • Patent number: 7268152
    Abstract: Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: September 11, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Mario G. Cardozo, Christian Hanke Justus Joachim Harcken, Thomas M. Kirrane, Daniel Kuzmich, John Robert Proudfoot, Hossein Razavi, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell
  • Patent number: 7211589
    Abstract: The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Z represents a bivalent organic group and the like of from 2 to 3 carbon atom(s) which may have a substituent; and R3 represents a carboxyl group and the like.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: May 1, 2007
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Akinori Akaike, Hachiro Sugimoto, Yukio Nishizawa, Masahiro Yonaga, Naoki Asakawa, Naoki Asai, Nariyasu Mano, Taro Terauchi, Takashi Doko
  • Patent number: 7176237
    Abstract: Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: February 13, 2007
    Assignee: The Trustees of Dartmouth College
    Inventors: Tadashi Honda, Frank G. Favaloro, Gordon W. Gribble, Michael B. Sporn, Nanjoo Suh
  • Patent number: 7148255
    Abstract: The invention relates to compounds of formula I wherein R1, R2, R3, R4, R5, R6, R8, R8?, R9, W, X, A1, A2, a, b and c have the significances given in the specification, and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites on warm-blooded animals.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: December 12, 2006
    Assignee: Novartis Animal Health US, Inc.
    Inventors: Pierre Ducray, Thomas Goebel, Jacques Bouvier, Corinne Durano
  • Patent number: 7041844
    Abstract: The present invention relates to an antiandrogen compound and a method of treating prostate cancer in a patient utilizing the compound. The present invention also relates to a pharmaceutical composition which includes the compound.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: May 9, 2006
    Assignee: The University Of Tennessee Research Corporation
    Inventors: Duane D. Miller, Leonid I. Kirkovsky, James T. Dalton, Arnab Mukherjee
  • Patent number: 6992106
    Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: January 31, 2006
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
  • Patent number: 6958146
    Abstract: Various exemplary compounds, compositions and methods are disclosed. An exemplary composition includes an insecticide comprising a formula weight greater than approximately 220 and a compound comprising an insect stimulant and a formula weight less than approximately 220. An exemplary method includes applying an insecticide comprising a formula weight greater than approximately 220 and applying a compound comprising an insect stimulant and a formula weight less than approximately 220. Exemplary compounds optionally include semiochemicals of insects, plants and/or animals. Other exemplary compounds, compositions and/or methods are also disclosed.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: October 25, 2005
    Assignee: Bug Buster Ltd.
    Inventors: Leonard R. Askham, Charles F. Dunham, Leonard D. Felix, Jr.
  • Patent number: 6946426
    Abstract: Provided is a method of formulating hydrophobic pesticides comprising emulsifying an aqueous phase and a water-immiscible phase to form a formulation; wherein the aqueous phase is comprised of water and optionally a freeze/thaw agent, one or more emulsifiers, or combinations thereof, and the water-immiscible phase comprises the hydrophobic pesticide and one or more emulsifiers.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: September 20, 2005
    Assignee: FMC Corporation
    Inventors: Timothy M. Martin, MaryEllen Lavin
  • Patent number: 6903052
    Abstract: The invention concerns the use of certain compounds related to fatty acids to control nematodes that infest plants or the situs of plants. Nematodes that parasitize animals can also be controlled using the methods and composition of this invention. Certain of the useful compounds are fatty acid esters that are predicted inhibitors of nematode delta-12 fatty acid desaturases and can be, for example, from C16 to C20 in length.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: June 7, 2005
    Assignee: Divergence, Inc.
    Inventors: Deryck J. Williams, Andrew P. Kloek, Michelle Coutu Hresko
  • Patent number: 6881248
    Abstract: A paint composition containing an insecticide and piperonyl butoxide as a synergist.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: April 19, 2005
    Assignee: Institute for Medical Research
    Inventors: Han Lim Lee, Nazni Wasi Ahmad, Abdullah Abdul Ghani
  • Patent number: 6858588
    Abstract: The present invention relates to a novel nitrile glycoside of Formula I named NIAZIRIDIN and to analogues and derivatives thereof. The present invention also relates to a process for the isolation of a novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues by bioactivity-guided fractionation from the pods of Moringa oleifera. The present invention particularly relates to the bioenhancing activity of the novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues in enhancing bioactivity of commonly used antibiotics such as rifampicin, tetracycline and ampicillin against Gram (+) and (?) bacteria. The biomolecule also enhances the absorption of drugs, vitamins and nutrients through the gastro-intestinal membrane increasing their bio-availability. Therefore niaziridin can be used in combination therapy with drugs and nutrients resulting in reduced drug associated toxicity, reduced cost and duration of chemotherapy.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: February 22, 2005
    Assignee: Council of Scientific and Industrial Research
    Inventors: Suman Preet Singh Khanuja, Jai Shanker Arya, Ranganathan Santha Kumar Tiruppadiripuliyur, Dharmendra Saikia, Harpreet Kaur, Monika Singh, Subhash Chandra Gupta, Ajit Kumar Shasany, Mahendra Pandurang Darokar, Santosh Kumar Srivastava, Madan Mohan Gupta, Subash Chandra Verma, Anirban Pal
  • Publication number: 20040235908
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: June 16, 2004
    Publication date: November 25, 2004
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jonathan A. Pachter, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
  • Patent number: 6815465
    Abstract: The invention relates to compounds of general formula (I) wherein R stands for a group of general formula —COOR1, —CONR2R3, —CONR4CONR4R5 or —CH2OR6, wherein R1 stands for a C2-6 alkyl group; a C1-6 alkyl group substituted; or a C3-6 cycloalkyl group; R2 and R3 are identical or different and stand independently from each other for hydrogen atom or a C1-6 alkyl group which optionally may be substituted; a 5- or 6-membered cycloalkyl or a heteroaryl group; and their tautomers, solvates and the mixtures thereof and acid addition salts of these compounds. The invention also relates to pharmaceutical compositions comprising compounds of general formula (I) as active agent. The angiogenesis-inhibitors according to the invention inhibit the neovascularization in living tissues and as such can be used for preventing and inhibiting angiogenesis appearing in connection with tumor growth and for preventing the formation of tumor metastases.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: November 9, 2004
    Assignee: IVAX International GmbH
    Inventors: Nándor Makk, Gábor Ambrus, Anikó Tegdes, András Jeney, Ferenc Timár
  • Publication number: 20040214887
    Abstract: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Application
    Filed: December 23, 2003
    Publication date: October 28, 2004
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Publication number: 20040186147
    Abstract: There is disclosed a novel class of sulphonamido-substituted bridged bicycloalkyl derivatives comprising a substitute on the bridgehead position. The compounds modulate the production of the &bgr;-amyloid precursor protein, and hence are useful in the treatment of Alzheimer's Disease.
    Type: Application
    Filed: January 20, 2004
    Publication date: September 23, 2004
    Inventors: Jonne Clare Hannam, Timothy Harrison, Andrew Madin, Timothy Jason Sparey
  • Publication number: 20040180930
    Abstract: The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
    Type: Application
    Filed: October 9, 2003
    Publication date: September 16, 2004
    Inventors: Akinori Akaike, Hachiro Sugimoto, Yukio Nishizawa, Masahiro Yonaga, Naoki Asakawa, Naoki Asai, Nariyasu Mano, Taro Terauchi, Takashi Doko
  • Publication number: 20040171684
    Abstract: The invention is of an improved to topical medicament and associated methodology for use thereof, through the use of which aberrant fibrotic tissue manifestations involving scarring or sub-dermal plaque formations or accumulations may be effectively, cost effectively, and painlessly treated, one or more calcium channel blocker agents serve as the primary active ingredient of the present compositions and transdermal penetration agents or carriers are included to facilitate topical delivery of the active ingredient(s) to the intended, sub-dermal treatment site.
    Type: Application
    Filed: April 27, 2004
    Publication date: September 2, 2004
    Inventor: W. Jerry Easterling
  • Publication number: 20040171636
    Abstract: A pharmaceutical composition comprising therapeutically effective quantities of calcium channel blockers in combination with quinolines. In preferred embodiments, the invention further comprises quercetin. The components combine and interact in a manner to effectively treat viral infections.
    Type: Application
    Filed: December 22, 2003
    Publication date: September 2, 2004
    Inventor: Robert H. Keller
  • Publication number: 20040171593
    Abstract: This invention relates to treating an inflammatory disease by administering a phosphodiesterase 4 inhibitor in combination with an inhibitor of prostaglandin synthesis, NSAIDs being exemplary.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 2, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: Elizabeth T. Keating, James M. Kanagy
  • Publication number: 20040167185
    Abstract: In one aspect, the present invention provides a method of inhibiting an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with an amount of an Edg-3 receptor inhibitor sufficient to inhibit the Edg-3 receptor mediated biological activity. Preferably, the inhibitor is not a phospholipid.
    Type: Application
    Filed: January 16, 2004
    Publication date: August 26, 2004
    Inventors: Geetha Shankar, David Solow-Cordero, Juliet V. Spencer, Charles Gluchowski
  • Publication number: 20040162321
    Abstract: Compounds of Formula (I) 1
    Type: Application
    Filed: December 18, 2003
    Publication date: August 19, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Kuzmich, Thomas Wai-Ho Lee, John Robert Proudfoot, John Robinson Regan, David S. Thomson, Abdelhakim Hammach, Mark Stephen Ralph, Renee Zindell
  • Publication number: 20040157803
    Abstract: Certain fatty acids and related compounds useful in the control nematodes that infest plants or the situs of plants are described. Nematodes that parasitize animals can also be controlled using the methods and compounds of this invention.
    Type: Application
    Filed: September 4, 2003
    Publication date: August 12, 2004
    Inventors: Deryck J. Williams, Andrew P. Kloek, Michelle Coutu Hresko, Barry J. Shortt, Jennifer A. Davila-Aponte, John D. Bradley, James McCarter, Merry B. McLaird
  • Publication number: 20040152748
    Abstract: Antimicrobial compositions based on the synergistic combination of 2-methyl-3-isothiazolone and selected commercial microbicides where the compositions are substantially free of halogenated 3-isothiazolone, are disclosed. Particularly preferred are combinations of 2-methyl-3-isothiazolone together with benzoic acid, citric acid, sorbic acid, 1,2-dibromo-2,4-dicyanobutane, 1,3-dimethylol-5,5-dimethylhydantoin, phenoxyethanol, benzyl alcohol, zinc pyrithione or climbazole, that provide enhanced microbicidal efficacy at a combined active ingredient level lower than that of the combined individual 3-isothiazolone and commercial microbicide effective use levels.
    Type: Application
    Filed: September 18, 2003
    Publication date: August 5, 2004
    Inventors: Megan Anne Diehl, Eileen Fleck Warwick
  • Publication number: 20040152772
    Abstract: Provided is a group of active substances capable of inhibiting the proliferation of cancer cells and inhibiting inflammation, as well as suppressing bodily defense reactions to control autoimmune diseases, transplant rejections, and acute and chronic inflammatory reactions.
    Type: Application
    Filed: March 15, 2004
    Publication date: August 5, 2004
    Inventors: Erich Eigenbrodt, Stefan Muellner, Sybille Mazurek, Hugo Fasold
  • Publication number: 20040151747
    Abstract: Volatile impregnated substrates, such as wicks and mats, that can be used in a dispensing device that uses a heat source or otherwise uses active means to promote the release of the volatile material from the substrate are disclosed. The preferred substrate has a structure including sand particles adhered together by a binder to form a network of pores and passages. The binder is selected from thermoset polymeric materials and mixtures thereof. A volatile material is disposed in the pores before the substrate is installed in the dispensing device. The impregnated substrate is positioned in the dispensing device on or near the heat source of the dispensing device. The heat source is activated thereby elevating the temperature of the substrate such that volatile material is released from the pores. In one embodiment, the sand particles comprise silica sand and the binder is a cured novolac resin.
    Type: Application
    Filed: January 30, 2003
    Publication date: August 5, 2004
    Inventors: Brian T. Davis, Robert R. Emmrich, Michael J. Aulozzi, Padma Prabodh Varanasi, Michael C. Fryan, Kenneth J. Welch, Stanley J. Flashinski, Debra A. Strasser
  • Publication number: 20040127481
    Abstract: The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a patient through an inhalation route. The method comprises: a) heating a composition of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug degradation products.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 1, 2004
    Applicant: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Publication number: 20040126328
    Abstract: The present invention relates to the delivery of a migraine headache drug through an inhalation route. Specifically, it relates to aerosols containing a migraine headache drug that are used in inhalation therapy. In a method aspect of the present invention, a migraine headache drug is administered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition a migraine headache drug, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles aerosol comprising particles with less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering a migraine headache drug through an inhalation route is provided which comprises: a) a thin coating of an a migraine drug composition and b) a device for dispensing said thin coating as a condensation aerosol.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 1, 2004
    Applicant: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Publication number: 20040127487
    Abstract: An agent comprising the benzoic acid of formula (I) 1
    Type: Application
    Filed: December 18, 2003
    Publication date: July 1, 2004
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kousuke Tani, Kaoru Kobayashi, Takayuki Maruyama
  • Publication number: 20040116482
    Abstract: A potassium channel opener comprising a compound (e.g.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 17, 2004
    Inventors: Yuji Imaizumi, Tomohiko Ohwada
  • Publication number: 20040115732
    Abstract: The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinducer agonists and antagonists, as well as methods for regulating the activity of an autoinducer receptor, regulating biofilm formation, regulating growth or virulence of an organism in a subject, inhibiting the quorum sensing mechanism of an organism, and treating an infection in a subject caused by an organism possessing a quorum sensing mechanism which use the autoinducer analogs of the present invention.
    Type: Application
    Filed: August 8, 2003
    Publication date: June 17, 2004
    Inventors: Hiroaki Suga, Yigong Bu
  • Publication number: 20040091511
    Abstract: Material of electronics component and electronics components using the same material are provided. The material includes repellent that can withstand severe solder-mounting conditions, and the electronics components such as printed wiring boards can lasts repelling effect for a long period. The material is used in electronics components requiring a soldering process, and includes at least curable resin, filler and the repellent. The repellent has vapor pressure of less than 10,000 nPa at room temperature. Film is formed using the material at a given place of an electronics component such as a printed wiring board.
    Type: Application
    Filed: May 19, 2003
    Publication date: May 13, 2004
    Inventor: Kazumi Iwasaki
  • Patent number: 6730705
    Abstract: The invention relates to new alkoximinoacetic acid amides, a process for their preparation and their use as agents for combating pests.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: May 4, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Seitz, Gerd Hänssler, Klaus Stenzel
  • Patent number: 6713077
    Abstract: A method of preventing damage to the shoots and foliage of a plant by a pest includes treating the seed from which the plant grows with a composition that includes at one pyrethrin or synthetic pyrethroid. In another embodiment, the pesticide is not limited to pyrethrins or synthetic pyrethroids when the seed is a transgenic seed having at least one heterologous gene encoding for the expression of a protein having pesticidal activity against a first pest and the pesticide has activity against at least one second pest. Treated seeds are also provided.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: March 30, 2004
    Assignee: Monsanto Technology, LLC
    Inventor: Frank C. Kohn
  • Patent number: 6710071
    Abstract: This invention relates to a series of difluoromethylene aromatic ethers of the formula wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: March 23, 2004
    Assignee: Pfizer Inc
    Inventor: John Adams Lowe, III
  • Publication number: 20040053999
    Abstract: Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.
    Type: Application
    Filed: July 28, 2003
    Publication date: March 18, 2004
    Inventors: Norbert W. Bischofberger, Terrence C. Dahl, Michael J. M. Hitchcock, Choung U. Kim, Willard Lew, Hongtao Liu, Roger G. Mills, Matthew A. Williams
  • Publication number: 20040048834
    Abstract: New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, CN, halogen, C(═O)H, C(═O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form ═O; Y is NR1, OR1, PR1, SR1, or halogen, wherein the number of substituents R1 is selected to suit the valency and each R1 is independently selected of H, OH, C(═O)R′, P(═O)R′R″, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH,
    Type: Application
    Filed: August 18, 2003
    Publication date: March 11, 2004
    Inventors: Jose Luis Acena, Javier Adrjo, Carmen Cuevas, Pilar Gallego, Ignacio Manzanares, Simon Munt, Ignacio Rodriguez